Mounjaro (tirzepatide) Injection

Mounjaro (tirzepatide) is a prescription once-weekly injectable medication used to improve blood sugar control in adults with type 2 diabetes. It is a dual GIP and GLP-1 receptor agonist that helps regulate blood sugar, reduces appetite, increases feelings of fullness, and slows stomach emptying. Many patients also experience significant weight loss when used alongside a healthy diet and regular physical activity.

Available Strengths

• 2.5 mg
• 5 mg
• 7.5 mg
• 10 mg
• 12.5 mg
• 15 mg

Typical Dosing Schedule

• Weeks 1–4: 2.5 mg once weekly (starting dose)
• Weeks 5–8: 5 mg once weekly
• If additional blood sugar control is needed, the dose may be increased in 2.5 mg increments every 4 weeks:
  • 7.5 mg once weekly
  • 10 mg once weekly
  • 12.5 mg once weekly
  • 15 mg once weekly (maximum recommended dose)

Common Side Effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Stomach pain
• Decreased appetite
• Indigestion
• Fatigue

These side effects are generally mild to moderate and often improve as your body adjusts to the medication.

Benefits

• Helps lower blood sugar levels in adults with type 2 diabetes.
• Supports significant weight loss when combined with a healthy diet and regular exercise.
• Reduces appetite and helps control food cravings.
• Convenient once-weekly injection.
• May improve several cardiometabolic risk factors, including blood sugar, body weight, and blood pressure.

Important Safety Information

Mounjaro should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is not recommended during pregnancy. Always use Mounjaro exactly as prescribed by your healthcare provider and follow the recommended dose-escalation schedule to help minimize gastrointestinal side effects.